FX 201 - Flexion

Drug Profile

FX 201 - Flexion

Alternative Names: FX201 - Flexion; GQ 203

Latest Information Update: 20 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Baylor College of Medicine
  • Developer Flexion Therapeutics
  • Class Anti-inflammatories; Antirheumatics; Gene therapies; Non-opioid analgesics
  • Mechanism of Action Gene transference; Interleukin-1-Receptor-Antagonist-Protein-Stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Osteoarthritis

Most Recent Events

  • 13 Dec 2017 FX 201 licensed to Flexion
  • 13 Dec 2017 Preclinical trials in Osteoarthritis in USA (intra-articular)
  • 13 Dec 2017 Flexion expects to hold a pre-IND meeting with the US FDA in the first half of 2018
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top